<DOC>
	<DOCNO>NCT00267384</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled clinical trial perform assess effect N-acetylcysteine therapy incidence nephrotoxicity among patient hospitalize infection treat aminoglycosides ( AGs ) . Secondary goal study follow : comparison mortality rate , length hospitalization among patient treat N-acetylcysteine compare control group .</brief_summary>
	<brief_title>N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity</brief_title>
	<detailed_description />
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Patients hospitalize presumptive gramnegative infection , assess treat house staff require gentamycin therapy accord infectious disease specialist decision . 2 . Aged 18 90 . 3 . Recruitment time start gentamycin therapy initiation study intervention le 24 hour . 4 . Signed informed consent . 1 . Any known allergy intolerance one medication AG group . 2 . Any known allergy intolerance Nacetylcysteine . 3 . Any immunosuppressive therapy exclude steroid therapy . 4 . Pregnancy . 5 . HIV infection . 6 . Nonsepsisrelated neutropenia . 7 . An estimated creatinine clearance le 30 mL/min . 8 . Acute renal failure define elevation creatinine level 0.5 mg/dL patient 's baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Aminoglycosides</keyword>
</DOC>